Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker

Abstract

Conclusions: Serum TK1 protein and activity levels were significantly higher in CMT than in healthy dogs. Size exclusion chromatography demonstrated major differences in the molecular forms of sTK1 in ALL, healthy, and CMT dogs, with a large fraction of inactive TK1 protein in CMT. Our results showed that the sTK1 protein assay can differentiate benign tumors (early stage tumors) from healthy more efficiently than sTK1 activity assay. This preliminary data supports that sTK1 protein assay is clinically useful. Further studies are needed to evaluate the diagnostic or prognostic role of serum TK1 protein in CMTs.

Keywords

Canine serum thymidine kinase 1; sTK1 protein assays; Canine mammary tumors; Size exclusion chromatography; Anti-dog TK1 antibodies

Published in

BMC Veterinary Research
2014, volume: 10, article number: 228

SLU Authors

• Jagarlamudi, Kiran Kumar

  • Department of Animal Biosciences, Swedish University of Agricultural Sciences
    

• Saellström, Sara

  • Department of Clinical Sciences, Swedish University of Agricultural Sciences
    

• Rönnberg, Henrik

  • Department of Clinical Sciences, Swedish University of Agricultural Sciences
    

• Eriksson, Staffan

  • Department of Animal Biosciences, Swedish University of Agricultural Sciences
    

UKÄ Subject classification

Other Veterinary Science
Medical Bioscience

Publication identifier

• DOI: https://doi.org/10.1186/s12917-014-0228-1

Permanent link to this page (URI)

https://res.slu.se/id/publ/64898